Detalles de la búsqueda
1.
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma.
Blood
; 142(18): 1518-1528, 2023 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37506339
2.
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection.
Haematologica
; 2023 Nov 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-38031761
3.
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma.
Blood
; 134(16): 1337-1345, 2019 10 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-31484647
4.
CD200 genotype is associated with clinical outcome of patients with multiple myeloma.
Front Immunol
; 15: 1252445, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38455039
5.
Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma.
Front Immunol
; 14: 1158105, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37122695
6.
Assessment of the psychometric properties of the Spanish version of EORTC QLQ-MY20 and evaluation of health-related quality of Life outcomes in patients with relapsed and/or refractory multiple myeloma in the real-world setting in Spain: results from the CharisMMa study.
Leuk Lymphoma
; 64(11): 1847-1856, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37539698
7.
Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas.
Clin Lymphoma Myeloma Leuk
; 22(8): 635-642, 2022 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-35610120
8.
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma.
Clin Lymphoma Myeloma Leuk
; 22(9): e844-e852, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35688793
Resultados
1 -
8
de 8
1
Próxima >
>>